JPMorgan Chase & Co. Has Lowered Expectations for Hikma Pharmaceuticals (LON:HIK) Stock Price

Hikma Pharmaceuticals (LON:HIK) had its price target cut by analysts at JPMorgan Chase & Co. from GBX 2,500 to GBX 2,400 in a research report issued on Friday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 51.71% from the company’s previous close.

Several other brokerages also recently commented on HIK. Berenberg Bank reduced their target price on Hikma Pharmaceuticals from GBX 2,560 to GBX 2,510 and set a “buy” rating for the company in a report on Thursday, October 16th. Deutsche Bank Aktiengesellschaft cut their price objective on Hikma Pharmaceuticals from GBX 3,100 to GBX 2,850 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research note on Friday. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of GBX 2,416.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,582 on Friday. The firm has a market cap of £3.50 billion, a PE ratio of 9.47, a P/E/G ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82. The business has a fifty day simple moving average of GBX 1,730.88 and a 200-day simple moving average of GBX 1,894.04. Hikma Pharmaceuticals has a fifty-two week low of GBX 1,522 and a fifty-two week high of GBX 2,360.

Insider Buying and Selling at Hikma Pharmaceuticals

In other Hikma Pharmaceuticals news, insider Mazen Darwazah acquired 315,000 shares of Hikma Pharmaceuticals stock in a transaction that occurred on Thursday, November 6th. The stock was purchased at an average cost of GBX 1,601 per share, with a total value of £5,043,150. Also, insider Laura Balan Balan acquired 3,500 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were acquired at an average price of GBX 1,821 per share, with a total value of £63,735. Insiders have purchased 332,500 shares of company stock worth $533,130,500 over the last three months. 17.77% of the stock is owned by insiders.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.